Answers are grounded in this paper and cite their sources.
Tirzepatide is a novel dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) for type 2 diabetes or obesity. To explore the safety profile of tirzepatide in real-world clinical applications.
No takes yet. Share an insight, caveat, or question.
Huo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: